Concurrent Use of Opioids and Benzodiazepines (COB-
NQF Endorsement Status Endorsed
NQF ID 3389
Measure Type Process
Measure Content Last Updated 2021-06-30
Info As Of Not Available
Properties
Description Percentage of Medicaid beneficiaries age 18 and older with concurrent use of prescription opioids and benzodiazepines.
Numerator The number of individuals from the denominator with: Two or more prescription claims for any benzodiazepine (Table COB-B) with unique dates of service, AND Concurrent use of opioids and benzodiazepines for 30 or more cumulative days. Table COB-B. Benzodiazepinesa Benzodiazepine Medications Alprazolam Chlordiazepoxide Clobazam Clonazepam Clorazepate Diazepam Estazolam Flurazepam Lorazepam Midazolam Oxazepam Quazepam Temazepam Triazolam
Denominator Age 18 and older as of January 1 of the measurement year. Identify individuals with 2 or more prescriptions for opioids (Table COB-A) with unique dates of service, for which the sum of the days supply is 15 or more during the measurement year. Exclude individuals who met at least one of the following during the
Report Generated: Sun Oct 03 03:11:28 EDT 2021 | Page 1
Concurrent Use of Opioids and Benzodiazepines (COB-
measurement year: Hospice Cancer Diagnosis Table COB-A. Opioid Medications Opioid Medications Buprenorphinec Butorphanol Codeine Dihydrocodeine Fentanyld Hydrocodone Hydromorphone Levorphanol Meperidine Methadone Morphine Opium Oxycodone Oxymorphone Pentazocine Tapentadol Tramadol
Denominator Exclusions Beneficiaries with cancer are excluded from this measure and may be identified using the ICD-10 codes in Table COB-C, available at https://www.medicaid.gov/license-agreement.html file=%2Fmedicaid%2Fquality-of-care%2Fdownloads%2F2018-adult-non-hedis- value-set-directory.zip. The cancer exclusion criterion is for beneficiaries with a diagnosis code for cancer during the measurement year. Their initial diagnosis may have occurred previously; however, the diagnosis code for cancer must be present
Rationale Not Available
Evidence Not Available
Developer/Steward
Steward Pharmacy Quality Alliance
Contact Not Available
Measure Developer Not Available
Report Generated: Sun Oct 03 03:11:28 EDT 2021 | Page 2
Concurrent Use of Opioids and Benzodiazepines (COB-
Development Stage Fully Developed
Characteristics
Measure Type Process
Meaningful Measure Area Not Available
Healthcare Priority Making Care Safer by Reducing Harm Caused in the Delivery of Care eCQM Spec Available No
NQF Endorsement Status Endorsed
NQF ID 3389
Last NQF Update 2020-10-19
Target Population Age 18+
Target Population Age (High) Not Available
Target Population Age (Low) 18
Reporting Level Not Available
Conditions Substance Abuse
Subconditions Opioid Dependency
Care Settings Hospital Outpatient; Other; Outpatient
Groups
Core Measure Set Medicaid Adult Core Set
Measure Group Group Identifier
Adult Core Set
Report Generated: Sun Oct 03 03:11:28 EDT 2021 | Page 3
Concurrent Use of Opioids and Benzodiazepines (COB-
Measure Links
Measure Program: Medicaid
Info As Of Not Available
Program / Model Notes
Data Sources Claims Data
Purposes Not Available
Quality Domain Not Available
Reporting Frequency Not Available
Impacts Payment No
Reporting Status Active
Data Reporting Begin Date 2018-10-01
Data Reporting End Date Not Available
Measure Program Links https://www.medicaid.gov/
Report Generated: Sun Oct 03 03:11:28 EDT 2021 | Page 4